ACT Biotech Inc
 | This article needs additional citations for verification. (July 2022) |
ACT Biotech Inc is a San Francisco-based, privately held biopharmaceutical company focused on the development and commercialization of targeted cancer drugs.[1][2] It was founded in 2008.[3]
The Company's clinical stage pipeline includes:
- Telatinib, an oral kinase inhibitor for the first-line treatment of advanced gastric cancer. It has been granted Orphan Drug status by the U.S. Food and Drug Administration (FDA).[4] It has reported encouraging interim results from a phase II trial.[1]
- ACTB1003, an oral kinase inhibitor that targets cancer cells through multiple modes of action. It inhibits cancer cell growth by targeting the FGF receptor family, which are mutated in a number of human cancer types. ACTB1003 also directly induces apoptosis by targeting kinases downstream of the PI3K pathway, all at low nanomolar concentrations.[citation needed]
Other pipeline products include an oral Aurora A and B kinase inhibitor at the pre-IND stage, and an ABL tyrosine kinase inhibitor targeting the T315I mutant enzyme in pre-clinical development.[5][6]
References[edit]
- ^ a b "ACT BIOTECH Announces Positive Interim Phase 2 Results with Telatinib in First-line Gastric Cancer". 11 Oct 2010.
- ^ "ACT Biotech Acquires Clinical and Early Stage Oncology Portfolio Licenses From Bayer Healthcare". 7 May 2008. Archived from the original on 25 October 2016. Retrieved 23 January 2018.
- ^ Leuty, Ron (February 19, 2013). "ACT Biotech co-founder Ali Fattaey makes tracks to Curis". San Francisco Business Times. Retrieved October 24, 2016.
- ^ "ACT Biotech Receives Orphan Drug Designation for Telatinib, an Orally Available and Highly Selective Kinase Inhibitor, in". 2 June 2010.
- ^ Jim Kling (1 April 2011). "ACT Biotech Inc". Medtech Insight. Retrieved 22 February 2023.
- ^ "biotickr". biotickr. Retrieved 2022-10-23.